HomeEBS • NYSE
add
Emergent Biosolutions Inc
$6.25
Makalipas ang Oras ng Trabaho:(0.00%)0.00
$6.25
Sarado: Hun 13, 4:01:18 PM GMT-4 · USD · NYSE · Disclaimer
Nakaraang pagsara
$6.59
Sakop ng araw
$6.19 - $6.47
Sakop ng taon
$4.02 - $15.10
Market cap
339.24M USD
Average na Volume
1.26M
P/E ratio
-
Dividend yield
-
Primary exchange
NYSE
Mga balita tungkol sa merkado
Mga Financial
Income Statement
Kita
Net na kita
| (USD) | Mar 2025info | Y/Y na pagbabago |
|---|---|---|
Kita | 222.20M | -26.03% |
Gastos sa pagpapatakbo | 69.00M | -31.68% |
Net na kita | 68.00M | 655.56% |
Net profit margin | 30.60 | 920.00% |
Kita sa bawat share | 0.71 | 20.34% |
EBITDA | 75.20M | 12.57% |
Aktuwal na % ng binabayarang buwis | 26.64% | — |
Balance Sheet
Kabuuang asset
Kabuuang sagutin
| (USD) | Mar 2025info | Y/Y na pagbabago |
|---|---|---|
Cash at mga panandaliang investment | 149.10M | 89.94% |
Kabuuang asset | 1.43B | -20.93% |
Kabuuang sagutin | 873.40M | -23.37% |
Kabuuang equity | 552.70M | — |
Natitirang share | 54.28M | — |
Presyo para makapag-book | 0.65 | — |
Return on assets | 8.95% | — |
Return on capital | 10.57% | — |
Cash Flow
Net change in cash
| (USD) | Mar 2025info | Y/Y na pagbabago |
|---|---|---|
Net na kita | 68.00M | 655.56% |
Cash mula sa mga operasyon | -11.20M | 82.11% |
Cash mula sa pag-invest | 59.50M | 650.93% |
Cash mula sa financing | -400.00K | -100.98% |
Net change in cash | 47.20M | 244.34% |
Malayang cash flow | -30.29M | 51.86% |
Tungkol
Emergent BioSolutions Inc. is an American multinational specialty biopharmaceutical company headquartered in Gaithersburg, Maryland. It develops vaccines and antibody therapeutics for infectious diseases and opioid overdoses, and it provides medical devices for biodefense purposes.
Among the company's products are the controversial BioThrax, the only anthrax vaccine licensed by the U.S. Food and Drug Administration and Narcan for the emergency treatment of opioid overdose. The company also manufactures pharmaceuticals for infectious diseases like cholera and typhoid.
During the COVID-19 pandemic, Emergent BioSolutions also produced Johnson & Johnson/Janssen and Oxford–AstraZeneca vaccines at one of its plants; however, this was marked by contamination and other production issues, and millions of doses of vaccine had to be discarded. Wikipedia
Itinatag
Set 5, 1998
Headquarters
Website
Mga Empleyado
900
